Mednet Logo
HomeCardiology
Cardiology

Cardiology

Expert discussions on heart failure, arrhythmias, interventional procedures, and cardiovascular risk management.

Recent Discussions

How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?

2
2 Answers

Mednet Member
Mednet Member
Endocrinology · Brigham And Womens Hospital Endocrinology

SGLT2-inhibitors have been known to precipitate episodes of diabetic ketoacidosis(DKA) with glucose levels far lower than are usually seen in DKA. This has been called euglycemic DKA. SGLT-2 inhibitors cause an increase in the glucagon to insulin ratio, which promotes ketosis, as well as fluid loss ...

When do you think physicians should seriously consider prescribing PCSK9 inhibitors for the prevention of heart attack and stroke in people with ASCVD or diabetes, based on the results of the VESALIUS-CV trial?

3 Answers

Mednet Member
Mednet Member
Endocrinology · Newyork Presbyterian Columbia University Irving Medical Center

Although I checked 'high lipoprotein (a) as a reason to go with a PCSK9 first, I would almost never do it is practice. Statins first and then add a PCSK9 if LDL is above my goal for the patient. I might use a lower dose of the statin to get 35% lowering and then add the inhibitor if the patient was ...

When would you consider endomyocardial biopsy for newly noted LVH with genetic testing significant for MYH7 mutation but also a TTR VUS also present?

1 Answers

Mednet Member
Mednet Member
Cardiology · Brigham Health Inc

This is an interesting question. However, it is important to know further information about the patient, such as age, sex, family, history, and the specific variant of unknown significance in the TTR gene (since some so called variants of unknown significance have descriptions in the literature that...

For elderly patients (i.e. older than 80) with only one documented episode of paroxysmal atrial fibrillation following a stress event (such as acute illness/steroid administration) and a CHADsVASc score greater than 1, how would you counsel them on the risks/benefits of anticoagulation and subsequent monitoring for afib recurrence?

7
6 Answers

Mednet Member
Mednet Member
Cardiology · Lankenau Heart Group

If it were an isolated event, I would advocate continued monitoring for recurrence before starting an anticoagulant with the understanding that the risk of AF recurrence is relatively high.

How do you decide which patients with upper GI bleeds should be monitored on telemetry?

1
1 Answers

Mednet Member
Mednet Member
General Internal Medicine · University of Chicago

Telemetry use has some standard indications in GI bleeding, specifically for patients with hemodynamic instability and significant cardiac comorbidities. Such situations include unresolved hypotension, >4 units transfused, known arrhythmia, and severe HFrEF. In these cases, I’m worried about someone...

What is your approach to secondary stroke prevention in patients with atrial fibrillation and intracranial stenosis (>70%)?

8
6 Answers

Mednet Member
Mednet Member
Neurology · Harvard Medical School

The patient clearly needs to be on an anticoagulant for stroke prevention with atrial fibrillation and I would choose apixaban. If an antiplatelet is added to the apixaban, the risk of a major bleeding side effect is significantly increased. It is uncertain if apixaban is effective in reducing the r...

What patient factors do you consider when selecting between a small interfering RNA, like inclisiran, and PCSK9 inhibitors in patients with recent acute coronary syndrome?

1
2 Answers

Mednet Member
Mednet Member
Cardiology · UT Southwestern Medical Center

Insurance coverage and out-of-pocket costs usually drive my choice. It is fairly easy to get approval for evolocumab for most of my patients. I have had a hard time getting approval for inclisiran with the exception of those with traditional Medicare + supplemental medication coverage. I usually sta...

Is there a potential role that hormonal replacement therapy can play in contributing to the development of SCAD?

1 Answers

Mednet Member
Mednet Member
Cardiology · Ohio State University Cardiovascular Medicine

Spontaneous coronary artery dissection (SCAD) is an infrequent if not rare cause of acute coronary syndrome (ACS). SCAD is estimated to occur in 0.7-1.1% of acute infarctions. In patients, especially female, who present with an ACS but have a low risk profile for coronary disease, SCAD should be con...

In a patient with decompensated heart failure requiring urgent non-cardiac surgery, how much volume optimization do you pursue preoperatively, and at what point does the risk of further surgical delay outweigh the benefit of continued diuresis?

3 Answers

Mednet Member
Mednet Member
Hospital Medicine · Temple University Hospital

This is an interesting question and a challenging situation for a patient. I think that the ideal scenario would be for the patient to be euvolemic clinically prior to surgery. I am very aggressive with intravenous diuretics. I think that a discussion with the patient, with the surgeon, and with ane...

For patients admitted with acute decompensated heart failure, do you wait until the patient is euvolemic before ordering a TTE?

2
1 Answers

Mednet Member
Mednet Member
Hospital Medicine · Temple University Hospital

For patients with newly diagnosed CHF, I always get a TTE prior to discharge to establish a baseline study. It would help me identify valvular disease and pulmonary hypertension, or other structural problems. If a TTE would help you distinguish CHF from other volume overload conditions, then I would...